Why Pennant Group’s latest earnings matter for shareholders

Pennant Group (PNTG) kicked off 2026 with first quarter results that put fresh attention on the stock, as higher sales, firmer earnings and recent senior living expansions all landed within days.

The earnings report and senior living additions arrived alongside a sharp share price move, with a 1-day share price return of 9.84% and a year to date share price return of 28.39%, while the 3-year total shareholder return of 221.60% contrasts with a more modest 5-year total shareholder return of 8.54%. This suggests that recent momentum has been much stronger than the longer term picture.

If Pennant Group’s momentum has you thinking about what else is moving, it could be a good time to broaden your search and scan 18 top founder-led companies

With Pennant Group now trading at US$35.73 and sitting about 6.8% below the average analyst price target and at a sizable 50% discount to one intrinsic value estimate, you have to ask: is there still a buying opportunity here, or is the market already baking in future growth?

Most Popular Narrative: 6.4% Undervalued

Pennant Group’s most followed narrative puts fair value at $38.17, slightly above the last close at $35.73. This frames the recent earnings and AMED expansion in a tighter valuation range.

The accelerating demographic shift of an aging U.S. population is leading to rising demand for home health, hospice, and senior living services, as evidenced by Pennant's strong organic and acquisition-driven volume growth and robust occupancy/pricing trends in senior living, this ongoing demographic wave is likely to continue expanding Pennant's addressable market, supporting durable, long-term revenue growth.

Want to see what is behind that growth story, beyond headlines and quarterly beats? The narrative leans heavily on multi year revenue expansion, margin uplift and a future earnings base that needs to work hard to justify that fair value tag.

Result: Fair Value of $38.17 (UNDERVALUED)

However, investors still need to factor in reimbursement pressure from the proposed 2026 CMS home health rule, along with ongoing labor costs and staffing challenges that could squeeze margins.

Another angle on Pennant Group’s valuation

The popular narrative leans on future earnings and a fair value around $38.17, yet today the stock trades on a P/E of 41.2x versus a fair ratio of 27x, the US Healthcare industry at 22.4x and peers at 25.7x. That richer multiple can signal valuation risk if expectations slip, so how comfortable are you paying up for this story?

For a closer look at what the numbers imply about today’s price tag versus that fair ratio, take a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and expectations, the real question is how you read the balance of optimism and concern. If you want to act while the data is fresh, take a moment to weigh both sides through 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with one stock when a broader watchlist could surface opportunities you would otherwise miss, especially when fresh ideas are only a quick screen away.

• Spot potential value candidates early by scanning 51 high quality undervalued stocks, so you are not the last to notice when quality meets a cheaper price tag.
• Strengthen your focus on financial resilience by checking the solid balance sheet and fundamentals stocks screener (44 results), where companies aim to pair sturdier balance sheets with sound fundamentals.
• Hunt for off-the-radar opportunities by using the screener containing 23 high quality undiscovered gems, before these quieter stories attract wider attention and crowd your entry point.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.